TY - JOUR
T1 - Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
AU - Mitsunaga, S.
AU - Ikeda, M.
AU - Shimizu, S.
AU - Ohno, I.
AU - Furuse, J.
AU - Inagaki, M.
AU - Higashi, S.
AU - Kato, H.
AU - Terao, K.
AU - Ochiai, A.
N1 - Funding Information:
We thank Ms Kayo Takei, Ms Miho Akimoto, Ms Yuriko Sato, and Ms Youko Yamasaki of the National Cancer Center Hospital East for their secretarial support and Mr Ryuu Kasai of Chugai Pharmaceutical Co., Ltd. for support with the statistical analysis. This work was supported by Grants-in-aid for Cancer Research and for the Third-term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan; JSPS KAKENHI Grant Number 22790624; the National Cancer Center Research and Development Fund (23-A-2b); and Chugai Pharmacology Co. Ltd.
PY - 2013/5
Y1 - 2013/5
N2 - Background:With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).Methods:Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.Results:Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P=0.011 and P=0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.Conclusion: The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.
AB - Background:With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC).Methods:Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of the patients were scheduled to undergo systemic chemotherapy. Serum pro-inflammatory cytokines were measured using an electro-chemiluminescence assay method before chemotherapy. High cytokine levels were defined as values greater than the median. Clinical data were collected prospectively.Results:Sixty patients who received GEM were included in the analysis. High IL-6 and IL-1β levels were poor prognostic factors for overall survival in a multivariate analysis (P=0.011 and P=0.048, respectively). Patients with both a high IL-6 level and a high IL-1β level exhibited shortened overall and progression-free survival, a reduction in the tumour control rate, and a high dose intensity of GEM compared with patients with low levels of both IL-6 and IL-1β.Conclusion: The serum levels of IL-6 and IL-1β predict the efficacy of GEM in patients with advanced PC.
UR - http://www.scopus.com/inward/record.url?scp=84878562029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878562029&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.174
DO - 10.1038/bjc.2013.174
M3 - Article
C2 - 23591198
AN - SCOPUS:84878562029
SN - 0007-0920
VL - 108
SP - 2063
EP - 2069
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 10
ER -
